Jasper Therapeutics
Latest round
- Series A
Last raised
- Jan 2020
Total raised
- $49M
Investors
- 7
About Jasper Therapeutics
Founded in 2018 by Dr. Judith Shizuru and Dr. Susan Prohaska, and based in California, US, Jasper Therapeutics, Inc. is a biotechnology company that focuses on enabling cures with hematopoietic cells transplants. The company develops hematopoietic transplantations that are possible for all indications for all types of patients including infants, children, the elderly, and other fragile populations. In 2020, Jasper Therapeutics, Inc. In 2021, Jasper Therapeutics, Inc., a special purpose acquisition company (SPAC) for USD 100 million.00 per share. As of 2021, the company has evaluated JSP191 in over 90 healthy volunteers and patients. The company’s pipeline includes its flagship product JSP191, an antibody in clinical development as a conditioning agent to clear stem cells from bone marrow in patients undergoing a hematopoietic cell transplant, creating a space for the donor or gene-corrected transplanted stem cells to engraft. JSP191 is designed to address the limitations of current conditioning by replacing chemotherapy or radiation in patients undergoing curative hematopoietic stem cell transplants and gene therapies. JSP191’s conditioning is used for AML(acute myeloid leukemia)/ MDs (myelodysplastic syndromes), SCID(severe combined immunodeficiency), Fanconi’s Anemia, sickle cell disease, and gene therapy. Jasper also provides an engineered hematopoietic stem cell (eHSC) platform to improve the safety and increase the cure rate of allogeneic and autologous gene therapy grafts without the need for toxic conditioning. eHSCs could eliminate the risk of GvHD and the need for long-term immune suppression and have the potential to expand the number of donors available for any given patient. Jasper eHSC Grafts is utilized for Thalassemias, sickle cell diseases, and autoimmune diseases., plans on listing on the NASDAQ under the ticker symbol, JSPR. The company plans on utilizing the capital obtained from the merger to accelerate the development of a clinical-stage anti-CD117 antibody transplant conditioning agent and the eHSC platform.
Who invested in Jasper Therapeutics
7 investors across 2 rounds
See all investors in Jasper Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Jasper Therapeutics
Who invested in Jasper Therapeutics?
Jasper Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Jasper Therapeutics raised?
Jasper Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Jasper Therapeutics last raise money?
Jasper Therapeutics's most recent round on record is a Series A, in Jan 2020.
What does Jasper Therapeutics do?
Jasper Therapeutics is a biotechnology company.
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics is headquartered in Redwood City, US.
Which VCs invest in companies like Jasper Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Jasper Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Jasper Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.